Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adagrasib - Mirati Therapeutics

Next Previous
Drug Profile

Adagrasib - Mirati Therapeutics

Alternative Names: BMS-986503; KRAZATI; MRTX 849

Latest Information Update: 07 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; Mirati Therapeutics
  • Developer Bristol-Myers Squibb; Mirati Therapeutics; Novartis; Whitehawk Therapeutics; ZAI Lab
  • Class Acetonitriles; Antineoplastics; Halogenated hydrocarbons; Naphthalenes; Piperazines; Pyridones; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action B7-H1 antigen inhibitors; KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer
  • Phase II Solid tumours
  • Preclinical Bladder cancer

Most Recent Events

  • 05 Aug 2026 Mirati Therapeutics initiates a phase I pharmacokinetic trial (In volunteers ) in the USA (PO) , (NCT07723118)
  • 23 Jul 2026 Mirati Therapeutics plans a phase I pharmacokinetics trial in healthy volunteers in the USA (PO) in August 2026 , (NCT07723118)
  • 15 Jun 2026 Verastem Oncology complets phase I/II RAMP 204 trial in Non small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT05375994)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top